Concepedia

Walter L. Vervenne

WL

Statistics

Publications

17

Citations

2.2K

H-Index

15

Active since

2004

Affiliations

Deventer Ziekenhuis(Current)

Amsterdam UMC Location University of Amsterdam

Charité - Universitätsmedizin Berlin

Heidelberg University

University Hospital Heidelberg

Walter L. Vervenne is an author at Deventer Ziekenhuis specializing in medicine, pharmacology, and oncology.

Publications per year

2004–2021

17

Publications

17

Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer

Eric Van Cutsem, Helgi van de Velde, Petr Karásek et al. · Journal of Clinical Oncology · 2004 · 774 citations · Full text

, , +12

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

Eric Van Cutsem, Walter L. Vervenne, Jaafar Bennouna et al. · Journal of Clinical Oncology · 2009 · 643 citations · Full text

, , +12

Predictive Factors for Outcome in a Phase II Study of Gefitinib in Second-Line Treatment of Advanced Esophageal Cancer Patients

Maarten L. Janmaat, Mariëlle I. Gallegos-Ruiz, José Antonio Rodríguez et al. · Journal of Clinical Oncology · 2006 · 230 citations

, , +17

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer

Christian Eichelberg, Walter L. Vervenne, Maria De Santis et al. · European Urology · 2015 · 142 citations · Full text

, , +16

Randomized Double-Blind Phase II Trial Comparing Gemcitabine Plus LY293111 Versus Gemcitabine Plus Placebo in Advanced Adenocarcinoma of the Pancreas

Muhammad Wasif Saif, Helmut Oettle, Walter L. Vervenne et al. · The Cancer Journal · 2009 · 57 citations

, , +16

1–5 of 17